A client with schizophrenia is being treated with olanzapine (Zyprexa) 10 mg daily. The client asks the nurse how this medicine minimizes hallucinations. The nurse explains that the mechanism by which olanzapine controls the client's psychotic symptoms is believed to be what?

Choice A reason: Olanzapine does not primarily increase serotonin or norepinephrine. It blocks dopamine D2 and serotonin 5-HT2 receptors, reducing hallucinations driven by mesolimbic dopamine excess in schizophrenia. Increasing monoamines would exacerbate psychosis, not alleviate it, making this mechanism incorrect. Choice B reason: Olanzapine, an atypical antipsychotic, blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopamine signaling that causes hallucinations in schizophrenia. It also modulates serotonin 5-HT2 receptors, balancing limbic activity, making this the primary mechanism for controlling psychotic symptoms. Choice C reason: Decreasing neurotransmitter breakdown enzymes is the mechanism of MAOIs, not olanzapine. Olanzapine’s dopamine and serotonin receptor blockade reduces psychotic symptoms, not enzyme activity, making this choice irrelevant to its antipsychotic action in schizophrenia. Choice D reason: Olanzapine does not normalize serotonin, norepinephrine, and dopamine levels but blocks their receptors, particularly dopamine D2, to reduce hallucinations. Normalizing levels is not its mechanism, as schizophrenia involves dopamine hyperactivity, not deficiency, making this choice inaccurate.